ARTICLE | Clinical News
Ganaxolone: Phase III data
June 20, 2016 7:00 AM UTC
Marinus said it will discontinue development of ganaxolone to treat focal onset seizures after top-line data from a double-blind, international Phase III trial in 359 adults epileptics with drug-resis...